Cargando…

Cost effectiveness analysis of implementing tuberculosis screening among applicants for non-immigrant U.S. work visas

BACKGROUND: While persons who receive immigrant and refugee visas are screened for active tuberculosis before admission into the United States, nonimmigrant visa applicants (NIVs) are not routinely screened and may enter the United States with infectious tuberculosis. OBJECTIVES: We evaluated the co...

Descripción completa

Detalles Bibliográficos
Autores principales: Sayed, Bisma Ali, Posey, Drew L., Maskery, Brian, Wingate, La’Marcus T., Cetron, Martin S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761151/
https://www.ncbi.nlm.nih.gov/pubmed/33357237
http://dx.doi.org/10.1186/s41479-020-00078-z
_version_ 1783627501585563648
author Sayed, Bisma Ali
Posey, Drew L.
Maskery, Brian
Wingate, La’Marcus T.
Cetron, Martin S.
author_facet Sayed, Bisma Ali
Posey, Drew L.
Maskery, Brian
Wingate, La’Marcus T.
Cetron, Martin S.
author_sort Sayed, Bisma Ali
collection PubMed
description BACKGROUND: While persons who receive immigrant and refugee visas are screened for active tuberculosis before admission into the United States, nonimmigrant visa applicants (NIVs) are not routinely screened and may enter the United States with infectious tuberculosis. OBJECTIVES: We evaluated the costs and benefits of expanding pre-departure tuberculosis screening requirements to a subset of NIVs who arrive from a moderate (Mexico) or high (India) incidence tuberculosis country with temporary work visas. METHODS: We developed a decision tree model to evaluate the program costs and estimate the numbers of active tuberculosis cases that may be diagnosed in the United States in two scenarios: 1) “Screening”: screening and treatment for tuberculosis among NIVs in their home country with recommended U.S. follow-up for NIVs at elevated risk of active tuberculosis; and, 2) “No Screening” in their home country so that cases would be diagnosed passively and treatment occurs after entry into the United States. Costs were assessed from multiple perspectives, including multinational and U.S.-only perspectives. RESULTS: Under “Screening” versus “No Screening”, an estimated 179 active tuberculosis cases and 119 hospitalizations would be averted in the United States annually via predeparture treatment. From the U.S.-only perspective, this program would result in annual net cost savings of about $3.75 million. However, rom the multinational perspective, the screening program would cost $151,388 per U.S. case averted for Indian NIVs and $221,088 per U.S. case averted for Mexican NIVs. CONCLUSION: From the U.S.-only perspective, the screening program would result in substantial cost savings in the form of reduced treatment and hospitalization costs. NIVs would incur increased pre-departure screening and treatment costs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41479-020-00078-z.
format Online
Article
Text
id pubmed-7761151
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77611512020-12-28 Cost effectiveness analysis of implementing tuberculosis screening among applicants for non-immigrant U.S. work visas Sayed, Bisma Ali Posey, Drew L. Maskery, Brian Wingate, La’Marcus T. Cetron, Martin S. Pneumonia (Nathan) Research BACKGROUND: While persons who receive immigrant and refugee visas are screened for active tuberculosis before admission into the United States, nonimmigrant visa applicants (NIVs) are not routinely screened and may enter the United States with infectious tuberculosis. OBJECTIVES: We evaluated the costs and benefits of expanding pre-departure tuberculosis screening requirements to a subset of NIVs who arrive from a moderate (Mexico) or high (India) incidence tuberculosis country with temporary work visas. METHODS: We developed a decision tree model to evaluate the program costs and estimate the numbers of active tuberculosis cases that may be diagnosed in the United States in two scenarios: 1) “Screening”: screening and treatment for tuberculosis among NIVs in their home country with recommended U.S. follow-up for NIVs at elevated risk of active tuberculosis; and, 2) “No Screening” in their home country so that cases would be diagnosed passively and treatment occurs after entry into the United States. Costs were assessed from multiple perspectives, including multinational and U.S.-only perspectives. RESULTS: Under “Screening” versus “No Screening”, an estimated 179 active tuberculosis cases and 119 hospitalizations would be averted in the United States annually via predeparture treatment. From the U.S.-only perspective, this program would result in annual net cost savings of about $3.75 million. However, rom the multinational perspective, the screening program would cost $151,388 per U.S. case averted for Indian NIVs and $221,088 per U.S. case averted for Mexican NIVs. CONCLUSION: From the U.S.-only perspective, the screening program would result in substantial cost savings in the form of reduced treatment and hospitalization costs. NIVs would incur increased pre-departure screening and treatment costs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41479-020-00078-z. BioMed Central 2020-12-25 /pmc/articles/PMC7761151/ /pubmed/33357237 http://dx.doi.org/10.1186/s41479-020-00078-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Research
Sayed, Bisma Ali
Posey, Drew L.
Maskery, Brian
Wingate, La’Marcus T.
Cetron, Martin S.
Cost effectiveness analysis of implementing tuberculosis screening among applicants for non-immigrant U.S. work visas
title Cost effectiveness analysis of implementing tuberculosis screening among applicants for non-immigrant U.S. work visas
title_full Cost effectiveness analysis of implementing tuberculosis screening among applicants for non-immigrant U.S. work visas
title_fullStr Cost effectiveness analysis of implementing tuberculosis screening among applicants for non-immigrant U.S. work visas
title_full_unstemmed Cost effectiveness analysis of implementing tuberculosis screening among applicants for non-immigrant U.S. work visas
title_short Cost effectiveness analysis of implementing tuberculosis screening among applicants for non-immigrant U.S. work visas
title_sort cost effectiveness analysis of implementing tuberculosis screening among applicants for non-immigrant u.s. work visas
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761151/
https://www.ncbi.nlm.nih.gov/pubmed/33357237
http://dx.doi.org/10.1186/s41479-020-00078-z
work_keys_str_mv AT sayedbismaali costeffectivenessanalysisofimplementingtuberculosisscreeningamongapplicantsfornonimmigrantusworkvisas
AT poseydrewl costeffectivenessanalysisofimplementingtuberculosisscreeningamongapplicantsfornonimmigrantusworkvisas
AT maskerybrian costeffectivenessanalysisofimplementingtuberculosisscreeningamongapplicantsfornonimmigrantusworkvisas
AT wingatelamarcust costeffectivenessanalysisofimplementingtuberculosisscreeningamongapplicantsfornonimmigrantusworkvisas
AT cetronmartins costeffectivenessanalysisofimplementingtuberculosisscreeningamongapplicantsfornonimmigrantusworkvisas